TALKMED GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.42 SGD | 0.00% |
|
-1.18% | +10.53% |
| Sales 2022 | 76.6M 56.23M | Sales 2023 | 83.79M 61.51M | Capitalization | 504M 370M |
|---|---|---|---|---|---|
| Net income 2022 | 30M 22.02M | Net income 2023 | 32M 23.49M | EV / Sales 2022 | 5.94 x |
| Net cash position 2022 | 74.16M 54.44M | Net cash position 2023 | 80.72M 59.26M | EV / Sales 2023 | 5.05 x |
| P/E ratio 2022 |
17.4
x | P/E ratio 2023 |
15.7
x | Employees | 232 |
| Yield 2022 |
7.5% | Yield 2023 |
5.79% | Free-Float | 14.44% |
More Fundamentals
* Assessed data
More news
| 1 week | -1.18% | ||
| Current month | +16.67% | ||
| 1 month | +15.07% | ||
| 3 months | +13.51% | ||
| 6 months | +7.69% | ||
| Current year | +10.53% |
1 week
0.41
0.43
1 month
0.360.46
Current year
0.360.46
1 year
0.360.46
3 years
0.360.46
5 years
0.330.55
10 years
0.330.95
| Managers | Title | Age | Since |
|---|---|---|---|
Peng Tiam Ang
CEO | Chief Executive Officer | 65 | 13-09-09 |
Boon Yong Lee
DFI | Director of Finance/CFO | - | - |
Kei Siong Khoo
COO | Chief Operating Officer | 62 | 13-09-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yih Pin Sitoh
BRD | Director/Board Member | 60 | 13-12-22 |
| Chairman | 83 | 13-12-22 | |
Swee Yam Sim
BRD | Director/Board Member | 68 | Dec. 31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.42 | 0.00% | 26 100 |
| 24-04-17 | 0.42 | +2.44% | 7,000 |
| 24-04-16 | 0.41 | -3.53% | 9,700 |
| 24-04-12 | 0.425 | 0.00% | 30,000 |
| 24-04-11 | 0.425 | 0.00% | 52,200 |
Delayed Quote Singapore S.E., April 18, 2024 at 01:01 am EDT
More quotes
TalkMed Group Limited is a Singapore-based investment holding company. The Company provides medical oncology and palliative care healthcare services in Singapore. Its oncology specialist specializes in providing medical oncology services targeting various cancers, such as breast cancer, colon cancer, lung cancer, liver, biliary and pancreatic cancers, gastro-intestinal cancers, head and neck cancers, leukemia, hematology malignancies and brain cancer. The Company, through the Parkway Cancer Centre (PCC)-vehicle, offers a support system to cater to the psychosocial needs of its patients and their families. The Company, through Singapore Cancer Centre (SCC) and the Parkway Cancer Centre (PCC) vehicle, provides CANSCREEN, a screening program that provides screening for individuals at a higher risk of getting cancer. The Company offers cellular and gene therapy related products and services. It also operates in Vietnam, Hong Kong and the People's Republic of China.
Calendar
2024-04-17
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +10.53% | 409M | |
| -12.37% | 86.47B | |
| +9.63% | 82.27B | |
| +10.85% | 29.43B | |
| -12.50% | 16.82B | |
| -5.06% | 15.89B | |
| -8.78% | 14.1B | |
| +1.87% | 12.05B | |
| -30.00% | 12.01B | |
| +20.51% | 11.19B |
- Stock Market
- Equities
- 5G3 Stock
